FDMT Historical Balance Sheet

FDMT Stock

USD 3.63 0.07 1.97%

Trend analysis of 4D Molecular Therapeutics balance sheet accounts such as Total Current Liabilities of 17 M or Total Stockholder Equity of 536.1 M provides information on 4D Molecular's total assets, liabilities, and equity, which is the actual value of 4D Molecular Therapeutics to its prevalent stockholders. By breaking down trends over time using 4D Molecular balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining 4D Molecular Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether 4D Molecular Therapeutics is a good buy for the upcoming year.

4D Molecular Inventory

(6.99 Million)

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in 4D Molecular Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

About FDMT Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of 4D Molecular Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. 4D Molecular Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of 4D Molecular and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which FDMT currently owns. An asset can also be divided into two categories, current and non-current.

4D Molecular Balance Sheet Chart

At this time, 4D Molecular's Non Current Liabilities Total is comparatively stable compared to the past year. Other Stockholder Equity is likely to gain to about 1.1 B in 2025, whereas Property Plant And Equipment Net is likely to drop slightly above 20.9 M in 2025.

Total Assets Other Current Liab Total Current Liabilities Other Liab

Add Fundamental

Total Assets

Total assets refers to the total amount of 4D Molecular assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in 4D Molecular Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on 4D Molecular balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of 4D Molecular Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from 4D Molecular's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into 4D Molecular Therapeutics current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in 4D Molecular Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

	2022	2023	2024	2025 (projected)
Other Current Liabilities	6.7M	12.0M	18.9M	19.8M
Total Assets	261.8M	339.9M	560.4M	588.4M

Other Current Liab Total Assets

4D Molecular balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Property Plant And Equipment Gross	Total Current Assets
Total Assets		0.98	0.91	0.67	-0.9	0.91	0.82	-0.75	-0.69	-0.95	0.86	0.77	0.92	0.58	0.8	0.92	0.26	0.86	0.87	-0.41	0.89	0.96	0.19	0.99	0.93	0.92
Other Current Liab	0.98		0.91	0.75	-0.87	0.84	0.79	-0.74	-0.6	-0.97	0.83	0.68	0.94	0.66	0.8	0.87	0.29	0.79	0.89	-0.33	0.85	0.95	0.11	0.96	0.92	0.87
Total Current Liabilities	0.91	0.91		0.58	-0.87	0.84	0.87	-0.65	-0.7	-0.9	0.9	0.74	0.8	0.48	0.93	0.95	0.38	0.91	0.98	-0.33	0.93	0.86	0.16	0.88	0.84	0.96
Total Stockholder Equity	0.67	0.75	0.58		-0.38	0.44	0.3	-0.42	-0.17	-0.68	0.3	0.24	0.71	0.81	0.38	0.52	0.31	0.39	0.58	-0.22	0.47	0.64	-0.33	0.66	0.52	0.52
Other Liab	-0.9	-0.87	-0.87	-0.38		-0.87	-0.92	0.8	0.77	0.9	-0.95	-0.83	-0.79	-0.34	-0.91	-0.89	-0.27	-0.87	-0.85	0.29	-0.88	-0.9	-0.3	-0.87	-0.93	-0.89
Net Tangible Assets	0.91	0.84	0.84	0.44	-0.87		0.83	-0.67	-0.88	-0.83	0.89	0.93	0.72	0.26	0.76	0.94	0.21	0.95	0.78	-0.62	0.96	0.83	0.33	0.94	0.84	0.93
Property Plant And Equipment Net	0.82	0.79	0.87	0.3	-0.92	0.83		-0.87	-0.67	-0.88	0.94	0.72	0.76	0.31	0.89	0.87	0.04	0.88	0.9	-0.49	0.85	0.88	0.25	0.83	0.93	0.87
Current Deferred Revenue	-0.75	-0.74	-0.65	-0.42	0.8	-0.67	-0.87		0.39	0.87	-0.73	-0.48	-0.83	-0.49	-0.68	-0.65	0.19	-0.64	-0.73	0.49	-0.61	-0.9	-0.04	-0.78	-0.93	-0.65
Net Debt	-0.69	-0.6	-0.7	-0.17	0.77	-0.88	-0.67	0.39		0.56	-0.81	-0.99	-0.37	0.13	-0.7	-0.84	-0.39	-0.88	-0.6	0.44	-0.89	-0.55	-0.47	-0.7	-0.58	-0.83
Retained Earnings	-0.95	-0.97	-0.9	-0.68	0.9	-0.83	-0.88	0.87	0.56		-0.84	-0.65	-0.95	-0.66	-0.85	-0.86	-0.2	-0.81	-0.92	0.41	-0.83	-0.99	-0.02	-0.94	-0.98	-0.86
Accounts Payable	0.86	0.83	0.9	0.3	-0.95	0.89	0.94	-0.73	-0.81	-0.84		0.85	0.73	0.19	0.88	0.93	0.14	0.91	0.88	-0.38	0.92	0.84	0.49	0.85	0.88	0.93
Cash	0.77	0.68	0.74	0.24	-0.83	0.93	0.72	-0.48	-0.99	-0.65	0.85		0.48	-0.02	0.74	0.87	0.36	0.9	0.65	-0.46	0.92	0.65	0.45	0.78	0.68	0.87
Non Current Assets Total	0.92	0.94	0.8	0.71	-0.79	0.72	0.76	-0.83	-0.37	-0.95	0.73	0.48		0.78	0.68	0.74	0.07	0.65	0.81	-0.32	0.68	0.96	0.03	0.91	0.93	0.75
Non Currrent Assets Other	0.58	0.66	0.48	0.81	-0.34	0.26	0.31	-0.49	0.13	-0.66	0.19	-0.02	0.78		0.36	0.33	0.22	0.22	0.52	-0.06	0.27	0.63	-0.52	0.55	0.55	0.34
Other Assets	0.8	0.8	0.93	0.38	-0.91	0.76	0.89	-0.68	-0.7	-0.85	0.88	0.74	0.68	0.36		0.87	0.46	0.87	0.93	-0.22	0.88	0.79	0.1	0.76	0.82	0.87
Cash And Short Term Investments	0.92	0.87	0.95	0.52	-0.89	0.94	0.87	-0.65	-0.84	-0.86	0.93	0.87	0.74	0.33	0.87		0.32	0.97	0.9	-0.47	0.98	0.84	0.3	0.92	0.83	1.0
Net Receivables	0.26	0.29	0.38	0.31	-0.27	0.21	0.04	0.19	-0.39	-0.2	0.14	0.36	0.07	0.22	0.46	0.32		0.3	0.28	0.3	0.38	0.08	-0.27	0.19	0.06	0.33
Common Stock Total Equity	0.86	0.79	0.91	0.39	-0.87	0.95	0.88	-0.64	-0.88	-0.81	0.91	0.9	0.65	0.22	0.87	0.97	0.3		0.87	-0.6	0.99	0.78	0.25	0.88	0.81	0.97
Common Stock Shares Outstanding	0.87	0.89	0.98	0.58	-0.85	0.78	0.9	-0.73	-0.6	-0.92	0.88	0.65	0.81	0.52	0.93	0.9	0.28	0.87		-0.38	0.88	0.87	0.06	0.86	0.87	0.9
Non Current Liabilities Total	-0.41	-0.33	-0.33	-0.22	0.29	-0.62	-0.49	0.49	0.44	0.41	-0.38	-0.46	-0.32	-0.06	-0.22	-0.47	0.3	-0.6	-0.38		-0.5	-0.43	0.01	-0.54	-0.44	-0.47
Other Current Assets	0.89	0.85	0.93	0.47	-0.88	0.96	0.85	-0.61	-0.89	-0.83	0.92	0.92	0.68	0.27	0.88	0.98	0.38	0.99	0.88	-0.5		0.8	0.27	0.9	0.81	0.98
Other Stockholder Equity	0.96	0.95	0.86	0.64	-0.9	0.83	0.88	-0.9	-0.55	-0.99	0.84	0.65	0.96	0.63	0.79	0.84	0.08	0.78	0.87	-0.43	0.8		0.11	0.95	0.99	0.84
Total Liab	0.19	0.11	0.16	-0.33	-0.3	0.33	0.25	-0.04	-0.47	-0.02	0.49	0.45	0.03	-0.52	0.1	0.3	-0.27	0.25	0.06	0.01	0.27	0.11		0.17	0.14	0.29
Net Invested Capital	0.99	0.96	0.88	0.66	-0.87	0.94	0.83	-0.78	-0.7	-0.94	0.85	0.78	0.91	0.55	0.76	0.92	0.19	0.88	0.86	-0.54	0.9	0.95	0.17		0.93	0.92
Property Plant And Equipment Gross	0.93	0.92	0.84	0.52	-0.93	0.84	0.93	-0.93	-0.58	-0.98	0.88	0.68	0.93	0.55	0.82	0.83	0.06	0.81	0.87	-0.44	0.81	0.99	0.14	0.93		0.83
Total Current Assets	0.92	0.87	0.96	0.52	-0.89	0.93	0.87	-0.65	-0.83	-0.86	0.93	0.87	0.75	0.34	0.87	1.0	0.33	0.97	0.9	-0.47	0.98	0.84	0.29	0.92	0.83

Click cells to compare fundamentals

4D Molecular Account Relationship Matchups

4D Molecular balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	288.3M	353.5M	261.8M	339.9M	560.4M	588.4M
Other Current Liab	8.4M	9.0M	6.7M	12.0M	18.9M	19.8M
Total Current Liabilities	16.7M	16.3M	15.7M	19.0M	29.1M	17.0M
Total Stockholder Equity	256.4M	(207.0M)	(314.5M)	307.8M	510.6M	536.1M
Other Liab	15.3M	15.2M	2.8M	1.3M	1.2M	1.1M
Net Tangible Assets	(73.0M)	256.4M	319.1M	231.3M	266.0M	279.3M
Property Plant And Equipment Net	5.1M	29.0M	35.3M	31.7M	40.6M	20.9M
Current Deferred Revenue	6.6M	2.6M	884K	273K	257K	244.2K
Net Debt	(276.7M)	(299.0M)	(202.5M)	(234.4M)	(124.7M)	(131.0M)
Retained Earnings	(135.7M)	(207.0M)	(314.5M)	(415.3M)	(576.2M)	(547.4M)
Accounts Payable	1.8M	4.8M	3.3M	3.5M	4.4M	2.9M
Cash	276.7M	315.4M	218.6M	249.1M	149.3M	189.0M
Non Current Assets Total	5.7M	38.1M	41.3M	43.3M	125.5M	131.7M
Non Currrent Assets Other	602K	(58.5M)	1.1M	684K	84.8M	89.1M
Other Assets	429K	677K	602K	1.1M	1.2M	640.8K
Cash And Short Term Investments	276.7M	315.4M	218.6M	288.2M	424.9M	232.3M
Net Receivables	978K	1.5M	47K	700K	630K	620.8K
Common Stock Shares Outstanding	26.7M	27.7M	32.4M	39.1M	53.9M	32.1M
Liabilities And Stockholders Equity	288.3M	353.5M	(284.0M)	339.9M	560.4M	588.4M
Non Current Liabilities Total	15.2M	18.0M	14.8M	13.1M	20.6M	35.8M
Other Current Assets	8.9M	8.5M	7.0M	8.4M	10.1M	6.3M
Other Stockholder Equity	103.7M	526.5M	547.0M	723.1M	1.1B	1.1B
Total Liab	31.9M	560.5M	30.5M	32.1M	49.8M	47.3M
Net Invested Capital	256.4M	319.1M	231.3M	307.8M	510.6M	536.1M
Property Plant And Equipment Gross	5.1M	34.3M	43.1M	43.6M	57.2M	60.1M
Total Current Assets	282.7M	315.4M	220.5M	296.6M	434.9M	236.7M
Accumulated Other Comprehensive Income	(288.3M)	(423K)	(1.2M)	16K	18.4K	19.3K
Non Current Liabilities Other	1.9M	17.8M	14.6M	248K	193K	183.4K
Net Working Capital	265.9M	239.9M	204.8M	277.6M	405.8M	211.5M
Property Plant Equipment	5.0M	5.1M	29.0M	22.3M	25.6M	26.9M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for FDMT Stock Analysis

When running 4D Molecular's price analysis, check to measure 4D Molecular's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 4D Molecular is operating at the current time. Most of 4D Molecular's value examination focuses on studying past and present price action to predict the probability of 4D Molecular's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 4D Molecular's price. Additionally, you may evaluate how the addition of 4D Molecular to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

FDMT Historical Balance Sheet

4D Molecular Inventory

(6.99 Million)

About FDMT Balance Sheet Analysis

4D Molecular Balance Sheet Chart

Total Assets

Total Current Liabilities

4D Molecular balance sheet Correlations

4D Molecular Account Relationship Matchups

High Positive Relationship

High Negative Relationship

4D Molecular balance sheet Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for FDMT Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Cash And Short Term Investments
Net Invested Capital	+ 0.99	Total Assets
Other Current Assets	+ 0.99	Common Stock Total Equity
Property Plant And Equipment Gross	+ 0.99	Other Stockholder Equity
Other Current Liab	+ 0.98	Total Assets
Common Stock Shares Outstanding	+ 0.98	Total Current Liabilities

Other Stockholder Equity	- 0.99	Retained Earnings
Cash	- 0.99	Net Debt
Property Plant And Equipment Gross	- 0.98	Retained Earnings
Retained Earnings	- 0.97	Other Current Liab
Non Current Assets Total	- 0.95	Retained Earnings
Accounts Payable	- 0.95	Other Liab